Patent intelligence · US
US 8063248
Sphingosine kinase inhibitors
Sphingosine kinase inhibitors
Patent details — US 8063248
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 22, 2011
- Expiration
- Nov 17, 2031
- Applicant
- Apogee Biotechnology Corporation
- Claims
- 11
- CPC classes
- A61P, A61P1/00, A61P1/02, A61P1/04
Quick answer
US 8063248 (Sphingosine kinase inhibitors) is held by Apogee Biotechnology Corporation. Status: granted. Granted Nov 22, 2011. Expires Nov 17, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Apogee Biotechnology Corporation
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61P, A61P1/00, A61P1/02, A61P1/04, A61P11/00, A61P11/06
More from Apogee Biotechnology Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12410137
Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
granted -
US 12378231
Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
granted -
US 12358979
Antibodies that bind interleukin 13 and methods of use
granted -
US 8685936
Sphingosine kinase inhibitor prodrugs
granted -
US 8557800
Sphingosine kinase inhibitors
granted -
US 7338961
Sphingosine kinase inhibitors
granted
Frequently asked questions
What is US patent 8063248?
US 8063248 (Sphingosine kinase inhibitors) is held by Apogee Biotechnology Corporation. Status: granted. Granted Nov 22, 2011. Expires Nov 17, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8063248?
Apogee Biotechnology Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 8063248 expire?
Our index shows an expiration date of Nov 17, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.